What's new

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 33, Status: Authorised

Feb 11, 2025 - 13:21
 0
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 33, Status: Authorised
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 33, Status: Authorised
Read More

Tags:

Previous Article

Pfizer wins 2025 Super Bowl with ad's 'likeability,' while Hims & Hers' spot tak...

Next Article

Jakavi-H-C-002464-X-0070-G : EPAR - Assessment report - Variation

Related Posts

Human medicines European public assessment report (EPAR): Sapropterin Dipharma, sapropterin, Date of authorisation: 16/02/2022, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 20, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Feraccru, ferric maltol, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: P/0503/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 19, 2025  0

Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pregabalin, Date of authorisation: 10/04/2014, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 25, 2025  0